Whalesbook
Zydus Lifesciences Ki Q4 FY26 Ki Kahani: Good News, Bad News!
Zydus Lifesciences ne FY26 ke liye apne financial results reveal kar diye hain. Q4 mein company ka consolidated revenue 16.22% badhkar ₹7,587 Crore ho gaya. Aur poore saal ki baat karein toh revenue 16.81% badhkar ₹27,148 Crore tak pahunch gaya. Company ne Q4 mein ₹1,272.50 Crore ka Net Profit bhi report kiya hai, jo ki bahut achha number hai.
Dividend Ka Announcement
Company ke board ne shareholders ke liye 100% (matlab ₹1 per share) ka final dividend recommend kiya hai. Yeh performance par unka confidence dikhata hai.
Chinta Ki Baat: Borrowing Ka Explosion!
Ab aate hain woh khabar par jo investors ko thoda sochne par majboor kar sakti hai. Company ka consolidated current borrowing dekh lo bhai, yeh ₹8,581.50 Crore ho gaya hai! Pichle saal yeh sirf ₹31,695 Crore tha. Ye kafi bada jump hai aur isse interest expenses badh sakte hain.
One-Time Kharch Ka Factor
Is quarter mein kuch bade one-time kharch bhi hue hain. Company ne Astellas Pharma ko ₹3,975 Crore ka settlement payment kiya hai aur labor code changes ki wajah se ₹849 Crore ka liability bhi booked hai. In sab ke chalte reported profit par thoda asar pada hai.
Investors Kya Dekhenge?
Ab investors ki nazar is baat par rahegi ki company is badhte debt ko kaise manage karegi. Ek taraf revenue growth aur dividend hai, toh doosri taraf debt ka pressure. Dekhna hoga ki management debt kam karne ke liye kya strategy laata hai.